Rosalind Advisors’s Cellectar Biosciences CLRB Stock Holding History

Rosalind Advisors’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-122,385	Closed	-$7.86M	–	42
2024 Q3	$7.86M	Buy	122,385 +32,198	+36%	+$2.12M	5.03%	9
2024 Q2	$6.76M	Buy	90,187 +69,471	+335%	+$6.67M	5.21%	7
2024 Q1	$2.47M	Sell	20,716 -46,139	-69%	-$5M	2.31%	19
2023 Q4	$5.56M	Buy	+66,855	New	+$4.98M	4.58%	10

Other funds holding CLRB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rosalind Advisors's CLRB Position: Q4 2024 in Review

Rosalind Advisors sold out of Cellectar Biosciences (CLRB) in Q4 2024, closing a stake of 122,385 shares — an estimated $7.86M sold.

Rosalind Advisors first reported a position in CLRB in Q4 2023 and held it in 4 quarters. The position peaked at $7.86M in Q3 2024. 30 funds tracked by Wall St. Rank hold CLRB as of Q4 2024.

Rosalind Advisors reported no remaining Cellectar Biosciences position as of Q4 2024 after selling out during the quarter.
Rosalind Advisors sold 122,385 Cellectar Biosciences shares in Q4 2024, an estimated $7.86M.
Rosalind Advisors first reported a position in Cellectar Biosciences in Q4 2023 and held it in 4 quarters.
Rosalind Advisors's Cellectar Biosciences position peaked at $7.86M in Q3 2024.
30 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2024.

Based on Rosalind Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.